Post-earnings recap
Reported
Thu, Jul 28, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
AstraZeneca's earnings report showed a slight miss on EPS, but the stock still rose by 0.84%. This increase may reflect investor confidence in the company's ongoing research and development efforts, despite the lack of revenue data and guidance. The management's focus on their product pipeline suggests they are positioning for future growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.73 | N/A | -2.54% |
Management expressed a cautious optimism about the future, focusing on research and development. They reiterated their commitment to advancing their product pipeline.
Management highlighted ongoing investments in R&D as a priority.
They emphasized the importance of their pipeline for future growth.